| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | FIMM | pan-cancer | AAC | -0.021 | 0.9 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | 0.0046 | 0.9 |
| mRNA | NG-25 | GDSC1000 | pan-cancer | AAC | 0.0037 | 0.9 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | -0.0057 | 0.9 |
| mRNA | BRD-K27986637 | CTRPv2 | pan-cancer | AAC | 0.0078 | 0.9 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | 0.0051 | 0.9 |
| mRNA | BRD-K41334119 | CTRPv2 | pan-cancer | AAC | -0.0078 | 0.9 |
| mRNA | Bosutinib | GDSC1000 | pan-cancer | AAC | 0.0036 | 0.9 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | -0.0054 | 0.9 |
| mRNA | GNF-2 | GDSC1000 | pan-cancer | AAC | 0.0057 | 0.9 |